上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
hVEGF-IN-1 纯度: 98.56%
hVEGF-IN-1,一种喹唑啉衍生物,可以特异性结合内部核糖体进入位点 A (IRES-A) 中富含 G 的序列,并会使 G-四链体结构不稳定。在 SPR 实验中,hVEGF-IN-1 以 0.928 μM 的 Kd 值与 IRES-A (WT) 结合。hVEGF-IN-1 可通过降低 VEGF-A 蛋白表达来阻止肿瘤细胞迁移并抑制肿瘤生长。
hVEGF-IN-1 Chemical Structure
CAS No. : 1637443-98-1
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
1 mg | ¥1250 | In-stock | |
5 mg | ¥3900 | In-stock | |
10 mg | ¥6800 | In-stock | |
50 mg | 询价 | ||
100 mg | 询价 |
* Please select Quantity before adding items.
hVEGF-IN-1 相关产品
•相关化合物库:
- Bioactive Compound Library Plus
- Kinase Inhibitor Library
- Protein Tyrosine Kinase Compound Library
- Anti-Cancer Compound Library
- Differentiation Inducing Compound Library
- Reprogramming Compound Library
- Anti-Breast Cancer Compound Library
- Anti-Lung Cancer Compound Library
- Anti-Pancreatic Cancer Compound Library
- Anti-Blood Cancer Compound Library
- Angiogenesis Related Compound Library
- Targeted Diversity Library
- Anti-Liver Cancer Compound Library
- Anti-Colorectal Cancer Compound Library
生物活性 |
hVEGF-IN-1, a quinazoline derivative, could specifically bind to the G-rich sequence in the internal ribosome entry site A (IRES-A) and destabilize the G-quadruplex structure. hVEGF-IN-1 binds to the IRES-A (WT) with a Kd of 0.928 μM in SPR experiments. hVEGF-IN-1 could hinder tumor cells migration and repress tumor growth by decreasing VEGF-A protein expression[1]. |
IC50 & Target |
VEGFR[1] |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
体外研究 (In Vitro) |
hVEGF-IN-1 (compound 1) (1 nM-100 μM; 5 min) binds to IRES-A (WT) and IRES-A mutant RNA oligomer (IRES-MU1) with Kds of 1.29 and 13.4 μM by microscale thermophoresis (MST) measurements, respectively[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis[1]
|
||||||||||||||||
体内研究 (In Vivo) |
hVEGF-IN-1 (compound 1) (7.5 mg/kg; i.p. once daily for 20 d) inhibits tumor growth in a human breast tumor xenograft[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
|
||||||||||||||||
分子量 |
581.75 |
||||||||||||||||
Formula |
C34H43N7O2 |
||||||||||||||||
CAS 号 |
1637443-98-1 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
|
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 25 mg/mL (42.97 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务